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Background: Some children with asthma experience exacerbations despite long- 
acting beta2- agonist (LABA) treatment. While this variability is partly caused by 
genetic variation, no genome- wide study until now has investigated which genetic 
factors associated with risk of exacerbations despite LABA use in children with 
asthma. We aimed to assess whether genetic variation was associated with exacer-
bations in children treated with LABA from a global consortium.
Methods: A meta- analysis of genome- wide association studies (meta- GWAS) was 
performed in 1,425 children and young adults with asthma (age 6- 21 years) with 
reported regular use of LABA from six studies within the PiCA consortium using a 
random effects model. The primary outcome of each study was defined as any ex-
acerbation within the past 6 or 12 months, including at least one of the following: 1) 
hospital admissions for asthma, 2) a course of oral corticosteroids or 3) emergency 
room visits because of asthma.
Results: Genome- wide association results for a total of 82 996 common single nu-
cleotide polymorphisms (SNPs, MAF ≥1%) with high imputation quality were meta- 
analysed. Eight independent variants were suggestively (P- value threshold ≤5 × 10−6) 
associated with exacerbations despite LABA use.
Conclusion: No strong effects of single nucleotide polymorphisms (SNPs) on exacer-
bations during LABA use were identified. We identified two loci (TBX3 and EPHA7) 
that were previously implicated in the response to short- acting beta2- agonists 
(SABA). These loci merit further investigation in response to LABA and SABA use.
K E Y W O R D S
childhood asthma, exacerbations, genetic polymorphism, long- acting beta2- agonist, 
pharmacogenetics
Key Message
No strong effects of single nucleotide polymorphisms (SNPs) on exacerbations dur-
ing long- acting beta2- agonists use were identified. We identified two loci (TBX3 and 
EPHA7) that were previously implicated in response to short- acting beta2- agonists.
1  | INTRODUC TION
Inhaled corticosteroids (ICS) are the cornerstone of asthma treat-
ment. For patients poorly controlled on low- dose ICS, current guide-
lines recommend increasing the ICS dose or adding a long- acting 
beta2- agonist (LABA).1,2 Both are effective for asthma control, im-
proving lung function and/or reducing exacerbations.3- 5
Nevertheless, there is high variation in responsiveness to step 
up options such as adding LABA.6 Various factors contribute to this 
variation including suboptimal inhalation technique, poor adherence 
to treatment, comorbidities, psychosocial factors and/or continued 
environmental exposure to allergens or air pollution.7
Genetic variation has also been suggested to play an important 
role in determining response to LABA.8- 12 Contribution of genetic 
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factors to observed differences in bronchodilator response is esti-
mated to be 28.5% for short- acting beta2- agonists (SABA).13 The 
role of genetics in observed differences in occurrence of exacerba-
tions despite LABA use is thought to be similar or even more prom-
inent.14 However, in current clinical practice we cannot yet predict 
which patients benefit from LABA and which patients still exacer-
bate.15 In 2010, a report commissioned by the United States Food 
and Drug Administration (FDA), warned for severe asthma exacer-
bations in patients treated with LABA, questioning safety of adding 
LABA to the treatment of asthma in adults and children.16- 19 18% of 
the included asthma patients treated with only LABA had increased 
risk of worse outcomes, such as decline in lung function, severe ex-
acerbations and even death.20- 26 Currently, according to the guide-
lines for asthma management, and as the FDA recommends,27 LABA 
is always prescribed in combination with ICS to decrease these risks.
Several candidate gene studies in children and young adults 
with asthma investigating LABA pharmacogenetics were performed 
during the last decades.28- 32 Variation in the ADRB2 gene encoding 
the beta2- adrenergic receptor is known to predict part of LABA 
response, due to its pivotal role in the pharmacological mechanism 
of LABA. In 1992, nine single nucleotide polymorphisms (SNPs) in 
ADRB2 were identified in patients with asthma with use of asthma 
medication compared to healthy subjects.33 Three of these SNPs 
have been replicated in candidate gene studies.28- 32 Nonetheless, 
these studies may only have evaluated a small portion of the genomic 
variation estimated to be involved in LABA response heterogeneity.
To the best of our knowledge, no genome- wide association 
study (GWAS) of exacerbations despite LABA use has yet been con-
ducted in children and young adults with asthma.34 Given the large 
variation in LABA response among asthmatic patients and the sus-
pected genetic component responsible for this heterogeneity, we 
aimed to assess whether genome- wide genetic variation is associ-
ated with exacerbations in children treated with LABA within the 
Pharmacogenetics in Childhood Asthma (PiCA) consortium35 and 
whether we could validate the association of previously reported 
SNPs in a candidate gene study.
2  | METHODS
2.1 | Study populations
This meta- GWAS included all studies participating in PiCA35 with 
medication and genetic data available for at least 100 LABA users. 
Six independent studies were analysed: Genes- environments 
& Admixture in Latino Americans Study (GALA II),36 Study of 
African Americans, Asthma, Genes and Environments (SAGE),37 
Pharmacogenetics of Asthma medication in Children: Medication 
with ANti- inflammatory effects (PACMAN),38 Paediatric Asthma 
Gene Environment Study (PAGES),39 BREATHE32,40,41 and Singapore 
Cross Sectional Genetic Epidemiology Study (SCSGES).42 All studies 
were approved by local institutional review boards and all patients 
and/or parents provided informed consent. Further description of 
these studies is presented in Supplementary material S1. LABA use 
was reported via questionnaires or pharmacy data.
2.2 | Outcome definition
The presence or absence of any asthma exacerbation during 
6- 12 months in patients treated with LABA was considered as the 
outcome for LABA response. Exacerbations were evaluated as a 
binary outcome measure and were defined as any of these three 
asthma events within the past 6 or 12 months: (a) hospital admis-
sions, (b) a short course of oral corticosteroid use and (c) emergency 
visits. The control group of each study consisted of patients with 
absence of any exacerbations during 6- 12 months. The definition of 
exacerbations per study is described in Supplementary Material S1.
2.3 | Genome- wide genotyping and imputation
We reported the genotyping platforms of each study in Table 1. For 
further information regarding genotyping and quality control analy-
ses, we refer to the papers of the studies.36- 42
In all studies, imputation was carried out by means of the 
Michigan Imputation Server43 using the second release of the 
Haplotype Reference Consortium (HRC) (r1.1 2016) as reference 
panel.44 Haplotype reconstruction and imputation were performed 
with SHAPEIT45 and Minimac246 for all studies, respectively. An ex-
ception was SCGES which used IMPUTE v2.0 to perform imputa-
tion based on 1000 genomes HapMap CHB and CHD samples. Our 
meta- GWAS included a total of common 15,229,795 SNPs (MAF 
≥1%) with a high- quality imputation score (Rsq ≥0.3) in all six popu-
lations. Due to differences in genotyping platforms listed in Table 1, 
the total number of overlapping of genotyped or imputed SNPs in all 
six studies was 82 996.
2.4 | Association testing and meta- analysis
GWAS was carried out separately in all cohorts. Logistic regression 
was used to evaluate the association of genetic variants with LABA 
response heterogeneity in all studies by means of the binary Wald 
test implemented in PLINK 1.90b6 (BREATHE, PAGES, PACMAN 
and SCSGES) and EPACTS (GALA II and SAGE). The logistic regres-
sion models were adjusted for age (in years), sex and study- specific 
principal component (PC) scores of genetic ancestry to correct for 
potential bias due to population stratification. These were estimated 
using a PC analysis47 using EIGENSOFT (GALA II and SAGE) and 
PLINK 1.90b6 (BREATHE, PAGES, PACMAN, and SCGES).
The meta- analysis was conducted with GWAMA.48 
Heterogeneity was assessed using the I2 statistic and Cochrane's Q 
test.49 Due to variety in ethnicities of the included patients, a ran-
dom effect meta- analysis was performed. A genome- wide thresh-
old (P- value ≤ 5 × 10−6) was applied to select variants suggestively 
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associated with exacerbations despite LABA use and a threshold of 
≤5 × 10- 8 for genome- wide significant associations. R version 3.6.3 
(R Core team, Vienna) was used to generate the Manhattan plot and 
quantile- quantile (QQ) plots.
2.5 | Functional evaluation of variants
One independent variant per locus was defined after pairwise regres-
sions conditioned on the most significant variant for each locus with 
more than one association signal (R2 <0.3) using SNPsnap50 with 1000G 
phase 3 as reference. Based on data provided by Encyclopedia of DNA 
Elements (ENCODE),51 functional annotation and a search for evidence 
for significant expression quantitative trait loci (eQTL) for SNPs in high 
linkage disequilibrium (LD) (r2 >0.8) were performed for variants with at 
least suggestive association using HaploReg v4.1.52 To study relation-
ships between identified genetic variations and gene expression, the 
Portal for Genotype- Tissue Expression (GTEx)53 v8.0 was used.
2.6 | Validation of previously reported genes
Previous studies reported the association of three SNPs located 
within ADRB2: rs1042713, rs1042714 and rs180088834 with exac-
erbations despite LABA use. We attempted to validate the associa-
tion of these available variants with exacerbations despite LABA use 
using results of the current meta- GWAS.
2.7 | Sub- analysis in PASS
The independent SNPs in the meta- GWAS were further investigated 
in a subset of LABA users from the Pharmacogenetics of Adrenal 
Suppression study (PASS)54 using the same definition for exacerba-
tions as described above. The characteristics of PASS are described 
in Table 1 and Supplementary Information 2. PASS is a unique co-
hort with children concerned to have adrenal suppression and was in 
need of assessment of their adrenal function with a low- dose short 












Gender (% female) 35 42 47 42 45 44.0
Mean age, (SD) years 10.3 (3.5) 11.4 (3.1) 14.3 ± 3.3 14.7 ± 6.2 13.1 ± 3.3 11.2 ± 3.7
Recruitment country The Netherlands United Kingdom United States 
of America




At least 1 
exacerbation
9.0 44.8 64.2 32.3 73.2 86.9
OCS use (%) 6.3 41.5 45.6 16.2 49.7 53.5
Emergency asthma 
care (%)
4.7 NA 53.0 20.3 59.9 NA
Hospitalizations (%) NA 15.7 12.1 1.3 16.9 76.9
Ethnicity
% European 90.3 71.5 0.0 0.0 0.0 100.0
% Hispanic 0.6 0.0 0.0 0.0 100.0 0.0
% African 1.2 0.0 100.0 0.0 0.0 0.0
% Asian 0.6 2.0 0.0 99.8 0.0 0.0
% other (including 
mixed)
7.4 0.7 0.0 0.2 0.0 0.0
% Not answered 0.0 25.8 0.0 0.0 0.0 0.0
Proportion of LTRA 
users (%)
21.1% 52.4% 26.8% Unknown 42.8% 64.7%
























Available variants after 
QC
1.024.058 1.328.296 13.967.128 5.144.048 9.749.587 Not applicable
Abbreviations: NA: not available; OCS, oral corticosteroids; SD, standard deviation;
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Synacthen test. Therefore, we decided to perform a sub- analysis in-
stead of inclusion to the initial meta- GWAS.
3  | RESULTS
3.1 | Study populations
The characteristics of the study populations consisting of 1,425 chil-
dren treated with at least LABA and ICS are shown in Table 1. Analyses 
were performed in a subset of 175 patients with LABA use from 
PACMAN, 306 from BREATHE and PAGES, 149 from SAGE II, 463 
from SCSGES and 332 from GALA II. The proportion of exacerbations 
defined as oral corticosteroids (OCS) use was lower in PACMAN and 
SCSGES (6.3% and 16.2%, respectively) compared to other studies. 
GALA II had the highest numbers of OCS courses of the meta- GWAS 
(49.7%). The number of OCS courses was even higher in PASS (53.5%).
3.1.1 | Genome- wide association meta- analysis
The Q- Q plots did not provide evidence for genomic inflation due to 
population stratification in each study (Figure S1A- S1E). In the meta- 
analysis, no associations with asthma exacerbations were genome- wide 
significant (P- value ≤5 × 10- 8). However, 22 variants were suggestively 
associated with exacerbations (P- value ≤ 5 × 10- 6) in our meta- analysis 
of children and young adults with asthma (Table 2, Figure 1). The SNP 
rs7958534, located near TBX3, had the strongest signal. The G allele 
of this SNP was associated with increased risk of exacerbations (odds 
ratio (OR) 1.86 (95% confidence interval (CI) 1.47- 2.35; P = 1.15x10- 7). 
Among the 22 identified SNPs, eight independent signals were identi-
fied. The forest plots of these SNPs are represented in Supplementary 
Figure S4. Results of the sub- analysis of the independent SNPs in 359 
children from PASS are represented in Table S1. None of the SNPs were 
associated with increased risk of exacerbations.
3.2 | Functional evaluation of variants
Next, the eight independent SNPs resulting from the meta- GWAS 
were further investigated in GTEX.52 Here, the independent SNP 
rs4700987 (nearest gene: LOC105377766) has been described as a 
lung eQTL for zinc finger protein 62 (ZFP62)53 (Figure S2).
3.3 | Validation of previous reported LABA 
associations from candidate gene studies
Of the three previously reported SNPs, two were available in all co-
horts of the current meta- GWAS dataset. All three variants were 
F I G U R E  1   Manhattan plot of meta- analysed association results of exacerbations in children using long- acting beta2- agonists. 
Association results are shown as – log10P- value on the y- axis per chromosome on the x- axis. The blue line represents the suggestive 
significance threshold (P ≤ 5 × 10−6)
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not consistently associated with exacerbations despite LABA use 
(Figure S3). However, a sensitivity analysis in PACMAN in which we 
stratified for LABA users without leukotriene antagonist (LTRA) use 
shows a significant association for ADRB2 rs1042713, the A allele 
increased the risk of exacerbations: OR 7.39 (95% CI 1.95- 28.01, 
Table S2). A trend towards a similar association for rs1042713 (OR 
1.20 (95% CI 0.72- 2.00)) can be observed in the sensitivity analysis 
of LABA users without LTRA use, albeit not statistically significant 
(Table S3).
4  | DISCUSSION
To our knowledge, this study is the first meta- GWAS of asthma 
exacerbations in children and young adults treated with LABA, all 
GWAS included in this meta- GWAS have not been published before. 
We combined six international studies with genomic data of children 
and young adults with asthma and identified eight independent vari-
ants suggestively associated with exacerbations despite LABA. The 
effect size of the suggestive significant independent SNPs ranges 
from 0.27 to 2.80, which is common in GWAS in the field of asthma 
exacerbations in children.55 There were multiple SNPs identified 
near TBX3 and EPHA7 in the initial GWAS; genes previously impli-
cated in SABA response.
TBX3 encodes T- box transcription factor 3. It acts as a transcrip-
tional repressor with in vertebrate development, cell fate, cell differ-
entiation and dell- cycle progression.56 This gene could possibly play 
a role in asthma, since variants located near TBX3 have been identi-
fied in genetic and epigenetic studies focusing on asthma. However, 
little is known about the mechanism behind the association. In a 
whole- genome admixture mapping study, TBX3 was associated with 
differences in SABA response between 318 African- American and 
179 European adult patients with asthma.57 This study combined 
data from the Severe Asthma Research Program (SARP1- 2) and the 
Collaborative Study on the Genetics of Asthma (CSGA). Patients 
included in SARP1- 2 had severe asthma and were non- smokers or 
had mild- to- moderate asthma with a prebronchodilator FEV1 ≥80% 
predicted and treatment with either no or low- to- moderate dose 
ICS (<880 µg fluticasone or equivalent). CSGA included families 
with an asthmatic sibling pair from three ethnicities (Caucasian, 
African- American and Hispanic- American). In a GWAS of 38 199 
European adults with asthma with FEV1 as the outcome, TBX3 had 
the strongest signal (P- value: 2.50 × 10−12) and was replicated in a 
meta- GWAS with 54 550 European adults (P- value: 1.50 × 10−5).58 
The largest study in the initial GWAS was Generation Scotland: the 
Scottish Family Health Study (GS:SFHS), including volunteers across 
Scotland aged 18- 98 years. The majority of individuals in the replica-
tion study was from the UK BiLEVE study, which selected adults from 
the middle and extremes of the FEV1 distribution among both heavy 
smokers (mean 35 pack- years) and never smokers. This association 
has also been assessed in a subset of 5,062 children with asthma 
(8- 9 years) from Avon Longitudinal Study of Parents and Children 
(ALSPAC), but TBX3 was not in association (P- value: 3.17 × 10- 1).59 
ALSPAC included any newborn child with an estimated birth date 
between 1 April 1991 and 31 December 1992 from mothers in the 
old administrative county of Avon. The reported TBX3 rs10850377 
was in linkage equilibrium with our signal of TBX3 rs6489992,60 a 
regulatory region variant, showing that these were independent 
SNPs.
The ephrin- type A receptor 7 gene, EPHA7, has previously been 
found to be expressed in resected non- small cell lung cancer human 
specimens, but its role in relation to bronchodilators in asthma and 
COPD has not been studied extensively, and therefore, little is 
known about its role in the current observed association.61 A GWAS 
investigating SABA responsiveness in 5,789 moderate- to- severe 
COPD patients (GOLD stage 2 or greater and all former smokers) 
with African- American or European ethnicity found that EPHA7 
was genome- wide significant for an increased FEV1 post- SABA re-
sponse619. Subjects that experienced a recent COPD exacerbation 
were excluded. The reported EPHA7 rs17575208 was in linkage 
equilibrium with our signal of EPHA7 rs1947048,60 an intergenic 
variant, showing that these were independent SNPs. The other six 
identified independent SNPs and variants in linkage disequilibrium 
with these SNPs have not previously been identified, little informa-
tion exists about their pharmacogenetic role in the association with 
exacerbations despite LABA use.
In GTEX, rs4700987 (nearest gene: LOC105377766) has been 
described as a lung eQTL for ZFP62. Studies in humans investigating 
the function of ZFP62 are lacking, due to a previous murine study61 
it is hypothesized that this gene may be involved in muscular cell 
differentiation.
We were unable find the association with exacerbations for the 
eight independent SNPs in PASS, but all point estimates were in the 
same direction. The PASS study includes a specific study population. 
These children were concerned to have adrenal suppression and re-
quired assessment of their adrenal function with a low- dose short 
Synacthen test. Therefore, a reliable comparison of these children 
with the children included in the meta- GWAS cannot be made and 
results should be interpreted with caution. Some of the SNPs, in-
cluding SNPs near TBX3 and EPHA7, were not genotyped on arrays 
of the other meta- GWAS European cohorts BREATHE, PAGES and 
PACMAN. For these SNPs, we thus cannot conclude whether the 
effect is non- European or whether it is not shown due to limited 
Europeans having these SNPs genotyped. In both GWAS described 
above, European populations were included.58,60
In contrast to a previous meta- analysis of candidate gene studies 
in PiCA, this meta- GWAS did not identify an association between 
variation in ADRB2 and LABA response heterogeneity28,34(Fig-
ure S3). Reasons for not confirming the association are 1) that the 
numbers of populations that were included in the earlier published 
meta- analysis28 differ due to quality control measures and a larger 
part of the study population was examined, 2) our GWAS was based 
on LABA users with or without leukotriene antagonist (LTRA) use, 
while the previous meta- analysis only included LABA users with-
out LTRA, and 3) we also added other cohorts in this meta- GWAS 
compared to the previous meta- analysis leading to regression to the 
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mean. Nonetheless, a sensitivity analysis in PACMAN, BREATHE and 
PAGES for LABA users without LTRA showed that results were more 
similar to the previous results28 (Tables S2,S3).
Our study has strengths and limitations. First, we combined six 
paediatric asthma cohorts with different ethnicities, enlarging the 
sample size of the LABA meta- GWAS in children and young adults 
with asthma. Second, we identified novel loci possibly helping to in-
crease knowledge of genes that can identify which child with asthma 
would benefit from LABA. Two of these locations were near genes 
earlier reported in relation to bronchodilator responsiveness, in-
creasing the validity of our results.
We acknowledge the following limitations. First, despite being 
the largest GWAS in children and young adults with LABA, the in-
ability to reach genome- wide significance for some potentially im-
portant SNPs with respect to the odds of exacerbation may have 
been due to lack of power. Only a small number of children were 
treated with LABA in PASS, and this may have impacted associ-
ation finding. PASS participants were suspected to have adrenal 
suppression. The selection of participants in this study may have 
also led to our inability to identify similar associations for the eight 
independent SNPs. We also included a proportion of patients who 
used LTRA besides the LABA use in the GWAS (see for propor-
tions Table 1). The proportions differed per study, and this hetero-
geneity may have influenced the inability to reach genome- wide 
significant results. Second, ethnicities varied between included 
studies. There may be ethnic differences in response to LABA, 
making it more complex to discover SNPs associated with exac-
erbations despite LABA use. Accordingly, the wide confidence in-
tervals demonstrated for I2 potentially indicate the presence of 
a reasonable amount of heterogeneity, which is presumably due 
to the limited number of studies included in the meta- analyses.63 
Moreover, previous analysis of SAGE and GALA II genotyped with 
an array optimized for those admixed populations has revealed 
previously unknown SNPs for asthma exacerbations55 despite ICS 
use. It could also be that in addition to ethnic variation of LABA 
response or even in the absence of ethnic variation of LABA re-
sponse relevant SNPs were only genotyped in some of the sam-
ples thus decreasing power. Given the limited sample size in each 
study, we chose to ensure that the variants analysed were based 
on the largest sample size available, being shared by all the studies. 
This resulted in a limited number of total variants, but ensured 
the largest statistical power to detect associations. Therefore, fu-
ture studies should provide a higher genetic coverage, analysing a 
larger amount of SNPS. Third, although retrospective information 
of exacerbations is commonly used in genetic studies of children 
with asthma, we cannot ascertain the temporal relationship be-
tween LABA use and timing of the exacerbation. This may have 
led to non- differential outcome misclassification, which usually 
dilutes effect estimates towards null. Fourth, as we did not have 
data regarding adherence to LABA of all participants, it was not 
possible to adjust for adherence and this may have influenced the 
outcome.
To conclude, no strong effects of SNPs on exacerbations de-
spite LABA use were identified. Eight independent SNPs sugges-
tively associated with exacerbations were identified. Two of these 
independent SNPs were near genes previously associated with 
bronchodilator responsiveness (TBX3 and EPHA7), and these merit 
further investigation. This meta- GWAS contributes to knowledge 
of pharmacogenetic markers that can determine whether children 
experience exacerbations despite LABA use, potentially leading to 
further understanding of which patients would benefit from LABA 
treatment. Further investigation in future studies including data in 
children with exacerbations despite LABA use (such as the PACT 
trial64 and the PUFFIN trial65 once these are genome- wide geno-
typed) could potentially lead to more concise meta- GWAS results.
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